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Summary
Background: Statins are the most widely prescribed
drug available. Due to this reason, it is important to
understand the risks involved with the drug class
and individual statins.
Aim: We conducted a meta-analysis and employed
indirect comparisons to identify differing risk effects
across statins.
Design: We included any randomized clinical trial
(RCT) of atorvastatin, fluvastatin, lovastatin, pitavasta-
tin, pravastatin, rosuvastatin and simvastatin used for
cardiovascular disease event prevention. The main
outcome was adverse events [all-cause mortality, can-
cers, rhabdomylosis, diabetes, aspartate and alanine
aminotransferase (AST/ALT), and creatinine kinase
(CK) increases beyond the upper limit of normal].
In order to evaluate the relative effects of each
drug on adverse events, we calculated adjusted in-
direct comparisons of the adverse-event outcomes.
Results: Seventy-two trials involving 159 458 pa-
tients met our inclusion criteria. Overall, statin treat-
ments significantly increased the rate of diabetes
when compared to controls (OR: 1.09; 95% CI:
1.02–1.16) and elevated AST (OR: 1.31; 95% CI:
1.04–1.66) and ALT (OR: 1.28; 95% CI: 1.11–1.48)
levels when compared to controls. Using indirect
comparisons, we also found that atorvastatin signifi-
cantly elevated AST levels compared to pravastatin
(OR: 2.21; 95% CI: 1.13–4.29) and simvastatin sig-
nificantly increased CK levels when compared to
rosuvastatin (OR: 4.39; 95% CI: 1.01–19.07).
Higher dose studies had increased risk of AST
elevations.
Discussion: Although statins are generally well tol-
erated, there are risks associated with almost all
drugs. With few exceptions, statins appear to exert
a similar risk across individual drugs.
Introduction
HMG-CoA reductase inhibitors (statins) first ap-
peared commercially in the late 1970s to treat
high blood cholesterol levels and have gained wide-
spread acceptance since they have demonstrated
important reductions in cardiovascular morbidity
and overall mortality.1 Since then, statins have
been extensively studied in a large variety of patient
populations, including both primary and secondary
prevention of cardiovascular disease (CVD).2,3 Due
to their effectiveness, there is a widespread interest
in the use of statins for broad populations and two of
them (simvastatin and pravastatin) are available in
generic form. Statins may one day be widely
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available over the counter (OTC).4 Already, a 10mg
tablet of simvastatin is on sale OTC in the UK.
Statins are also a component of the poly-pill, a com-
bination strategy to reduce cardiovascular morbidity
using cholesterol lowering, blood pressure lowering
and blood thinning drugs.5
Since statins are prevalent in use, it is imperative
to understand the risks involved with taking these
medications. Known adverse events with statin ther-
apy range from raised liver enzymes in some pa-
tients to potentially fatal rhabdomyolysis in rare
occurrences, as occurred with cerivastatin before it
was taken off the market in 2001.6 Although these
events are well documented, recent evidence sug-
gests that statins can slightly increase the risk of de-
veloping diabetes mellitus.7 Large, up-to-date
systematic reviews with meta-analyses are essential
to provide clinicians, health economists and policy
makers with the most reliable, critically appraised
and precise estimates of treatment effects and to
monitor for rare adverse events. Therefore, we
updated previous meta-analyses of statin trials3,8–15
in an effort to assemble the totality of published
randomized control trial (RCT) evidence to date, in
order to assess adverse events associated with the
use of individual statin treatments.
Methods
Eligibility criteria
We included any RCT of atorvastatin, fluvastatin,
lovastatin, pravastatin, rosuvastatin and simvastatin
for CVD event prevention. Cerivastatin was not
included, as it has been withdrawn from the
market due to serious adverse events.6 Studies had
to compare a statin to placebo, standard therapy or
no-treatment and report on any of the following clin-
ically important cardiovascular outcomes: all-cause
mortality; CVD mortality; fatal myocardial infarction
(MI); non-fatal MI and major CV events (stroke,
revascularization). We excluded studies only report-
ing on surrogate outcomes (e.g. LDL and HDL
levels) and follow-up studies where randomization
had been subverted. We additionally excluded
head-to-head statin evaluations as we have reported
these elsewhere.16
Search strategy
In consultation with a medical librarian, we estab-
lished a search strategy (available from authors upon
request). We searched independently, in duplicate,
the following 12 databases (from inception to
December 2010: MEDLINE, EMBASE, Cochrane
CENTRAL, AMED, CINAHL, TOXNET, Development
and Reproductive Toxicology, Hazardous Substances
Databank, Psych-info and Web of Science, databases
that included the full text of journals, ScienceDirect
and Ingenta, including articles in full text from
1700 journals since 1993). In addition, we
searched the bibliographies of published systematic
reviews3,8–15 and health technology assessments.17–19
Finally, we searched our own comprehensive rolling
database of statin trials, updated annually. We also
contacted the authors of all trials for study clarifica-
tions, where required, and the authors of the only
individual patient data meta-analysis of statins that
included 14 trials.14,15 Searches were not limited by
language, sex or age.
Study selection
Two investigators (E.M., P.W.) working independ-
ently, in duplicate, scanned all abstracts and ob-
tained the full-text reports of records that indicated
or suggested that the study was a RCT evaluating
statin therapy on the outcomes of interest. After ob-
taining full reports of the candidate trials (either in
full peer-reviewed publication or press article), the
same reviewers independently assessed eligibility
from full-text papers.
Data collection
The same two reviewers conducted data extraction
independently using a standardized pre-piloted
form. The reviewers collected information about
the statin and type of interventions tested, the popu-
lation studied (age, sex and underlying conditions),
the treatment effect on specified outcomes and the
length of follow-up. Study evaluation included gen-
eral methodological quality features, including se-
quence generation, blinding, use of intent-to-treat
analysis, percentage of follow-up and allocation
concealment.20 We extracted data on the incidence
of the following clinically relevant adverse-event
outcomes: all-cause mortality, cancers, rhabdomy-
losis, diabetes, aspartate aminotransferase (AST), as-
partate aminotransferase (ALT) and creatinine kinase
(CK). We determined when an individual study re-
ported a priori the adverse events they would collect
and thresholds to define them. We entered the data
into an electronic database such that duplicate
entries existed for each study; when the two entries
did not match, we resolved differences through dis-
cussion and consensus.
Data analysis
In order to assess inter-rater reliability on inclusion
of articles, we calculated the phi (f) statistic that
provides a measure of inter-observer agreement
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independent of chance.21 For mortality outcomes,
we calculated the relative risk (RR) and appropriate
95% confidence intervals (95% CIs) of outcomes
according to the number of events reported in the
original studies or substudies intent-to-treat ana-
lyses. Where studies did not report intent to treat,
we analyzed outcomes as all-patients rando-
mized.22 In the case of an individual patient data
meta-analysis of 14 trials, we included outcomes
as reported by the meta-analysis, in correspondence
with the study’s authors. In the event of zero-
outcome events in one arm of a trial, we applied
the Haldane method and added 0.5 to each arm.23
We pooled studies as an analysis of all-statins com-
bined using the DerSimonian–Laird random effects
method,24 which recognizes and anchors studies as
a sample of all potential studies, and incorporates an
additional between-study component to the esti-
mate of variability.25 For non-mortality adverse
events, we calculated event rates using Peto’s odds
ratio.26 Peto’s odds ratios appears to provide the
least biased estimates and CI coverage with rare
events.27 Forest plots are displayed for each ana-
lysis, showing pooled estimates with 95% CIs, and
the overall DerSimmonian–Laird pooled estimate. We
tested for heterogeneity using the Cochran Q-test and
calculated the I2 statistic for each all-statin analysis
as a measure of the proportion of the overall vari-
ation that is attributable to between-study hetero-
geneity.28 We conducted a multivariable meta-
regression analysis to examine the impact of the
following co-variates, all chosen a priori: absolute
LDL change; proportion of individuals in trials that
were men; had a history of CHD, had a diagnosis of
diabetes or were hypertensive and current smokers
at baseline.29 We conducted a subgroup analysis
examining high doses of statins on adverse events.
In order to evaluate the relative effects of each
drug on adverse events, we calculated adjusted
indirect comparisons of the adverse-event out-
comes.30 We previously evaluated the impact of ad-
justed indirect comparisons in reference to another
strategy of evaluating indirect comparisons, the mul-
tiple treatment comparison meta-analysis and
demonstrated that they yield similar estimates
when dealing with star-shaped networks (where all
drugs have a mutual control).31 Analyses were con-
ducted using StatsDirect (version 2.5.2, www.stats-
direct.com) and the Canadian Agency for Drugs and
Technology Indirect Comparison software (version 1).
Role of the funding source
No funding sources had a role in study design, data
collection, data analysis, data interpretation or writ-
ing of the report. The writing group had full access to
all the data in the study and had final responsibility
for the decision to submit for publication.
Results
A total of 72 RCTs met our inclusion criteria (Figure 1).
Data were available on 159458 participants.
Appendix Table S1 displays the characteristics of
included studies and Appendix Table S2 displays
the criteria for defining adverse events and the stu-
dies that had a priori determined adverse events
as reported in the methods section of individual
RCTs. Women represented 30% of trial partici-
pants. The mean age of included participants was
59.8 (SD 5.99) years, trial averages ranging from
39 to 75 years. Trials used placebo, usual care, no
treatment or conventional therapy as inert controls.
Trials followed patients for a mean of 2.7 years
(SD 1.61), ranging from 0.5 to 6.1 years.
574 potentially relevant articles 
identified and screened for 
retrieval 
356 articles excluded based on 
title and abstract 
218 articles retrieved in full text 
for detailed evaluation 
139 articles excluded for the 
following reasons: 
• 12 head to head RCTs 
• 3 survival rates only 
• 9 follow up less than 6 
months 
• 65 subgroup analysis of 
included trials or 
duplicate reporting 
• 33 evaluated outcomes 
of no interest to this 
analysis 
• 4 non-randomized 
• 13 rationale, study 
protocol or baseline 
report
79 articles addressing topic of 
interest 
7 articles excluded for the 
following reasons: 
• 1 statin not compared 
with control 
• 2 events not clearly 
reported 
• 4 adverse event data 
not clear/ not available
72 RCTs included 
Figure 1. Study flow diagram.
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The mean pre-treatment LDL cholesterol was
4.61mmol/l (179.79mg/dl) and ranged from
2.43mmol/l (94.77mg/dl) to 5mmol/l (195mg/dl).
Methodological quality of included studies
We found that the reporting quality of studies varied.
Twenty-six studies reported how randomization se-
quence was generated in their primary publication.
Nineteen studies reported on how allocation to
groups was concealed. Sixty-four studies reported
on loss to follow-up. Four studies reported that the
primary results were based on a per-protocol ana-
lysis rather than intent to treat. Sixty-one studies re-
ported on at least one specific group being blinded
in the trial, typically patients and caregivers.
Deaths (all-cause)
There were a total of 13 577 deaths, including a
total of 6898 from confirmed vascular causes. In
all trials combined, there were a total of 6420
(7.4%) deaths among the 85 815 patients receiving
a statin and 7157 (8.9%) deaths among 79 866 pa-
tients receiving a control intervention. In total, this
represents an 11% reduction in all-cause mortality
(RR: 0.89, 95% CI 0.86–0.93, P4 0.0001; I2 = 11%,
P=0.21).
Adverse events
Data on first incident cancers recorded after ran-
domization were available from 33 RCTs.1,32–63
The incidence of cancers was not different between
statin groups and control groups [3706 (5.9%) vs.
3746 (6.0%); OR: 0.99, 95% CI 0.94–1.04,
P=0.69; I2 = 0%]. Rhabdomylosis information
was available from 36 RCTs,1,32–35,37–42,45–47,50–
54,56,58,59,61,63–75 enrolling a total of 139 029 indi-
viduals. We did not find a significant difference
between groups [179 (0.25%) statins vs. 170
(0.25%) controls; OR: 1.05, 95% CI 0.84–1.31,
P=0.70; I2 = 0%]. We evaluated incident diabetes
available from 16 RCTs enrolling 118 240 individ-
uals.33,34,39–43,47,52,54–56,59,65,68,76 When we evalu-
ated new incident diabetes, we found a significantly
increased rate of diabetes [2246 (3.8%) statins
vs. 2073 (3.5%) controls; OR: 1.09, 95% CI 1.02–
1.16, P=0.015; I2 = 11%]. We also examined
the impact of statins on elevated AST from 22
RCTs1,32–38,40,42,45,47,53,56,59,61,63,66,68,69,73,77 and
found a significant association [OR: 1.31, 95% CI
1.04–1.66, P=0.022; I2 = 42%]. The impact of sta-
tins on increased ALT levels from 20
RCTs1,35,36,39,41–43,45–47,50–52,54,58,59,64,71,75,78 also
showed a significant association [OR 1.28, 95% CI
1.11–1.48, P4 0.001; I2 = 0%]. The impact of
statins on CK increases beyond normal from 26
RCTs1,35–37,39–42,45–48,50,51,53,54,59,61,63,64,67–70,75,79
was not found to be significant [OR: 1.09, 95% CI
0.85–1.41, P=0.51; I2 = 10%].
In a subgroup analysis examining exclusively
high-dose statins, we found only an increased risk
of adverse events on the end point of AST elevation.
Cancer risk (two RCTs, OR 1.08, 95% CI 0.75–1.56,
P=0.64); rhabdomylosis (seven RCTs, OR 1.97,
95% CI 0.75–5.18, P=0.16); diabetes (two RCTs,
OR 1.22, 95% CI 1.05–1.43, P=0.01); AST eleva-
tions (five RCTs, OR 3.53, 95% CI 2.02–6.16,
P4 0.0001); ALT elevations (three RCTs, OR 1.43,
95% CI 0.65–3.14, P=0.36) and CK elevations
beyond normal (five RCTs, OR 0.91, 95% CI
0.12–7.01, P=0.93). AST elevation was significantly
different between lower and higher dose statins, dia-
betes incidence was not. Due to the small number of
individual RCTs for each statin evaluating high
doses, we did not find a significant effect for any
individual statin.
Atorvastatin
The analysis of atorvastatin is shown in Table 1.
Data on atorvastatin were available from 17
RCTs,45,49,51,53,58,61,65,66,70,72–74,77,80–83 6 of which
had recorded the incidence of cancer after random-
ization in 11 763 patients. No significance was
found for cancer incidence rates between treatment
and control groups [185 (3.12%) statin vs. 205
(3.52%) controls; OR: 0.90, 95% CI 0.74–1.11,
P=0.3214; I2 = 0%]. Rhabdomyolysis information
was available from 11 RCTs comprised of 26 067
patients. No significant difference was found be-
tween the treatment and control groups
[13 (0.10%) statin vs. 9 (0.07%) controls; OR:
1.38, 95% CI 0.61–3.13, P=0.4436; I2 = 0%]. No
meta-analysis could be performed on the incidence
of diabetes for atorvastatin as there was only one
study that contained data on this. The effect of ator-
vastatin on elevated AST levels from six RCTs was
found to be significant [83 (1.40%) statin vs. 32
(0.54%) controls; OR: 2.27, 95% CI 1.19–4.30,
P=0.0123; I2 = 41%], whereas the impact atorvasta-
tin had on increased ALT levels [two RCTs; 22
(1.07%) statin vs. 15(0.73%) controls; OR: 1.74,
95% CI 0.50–6.07, P=0.3877; I2 =NA] and
increased CK levels [five RCTs; 8 (0.18%) statin vs.
11 (0.24%) controls; OR: 1.21, 95% CI 0.19–7.92,
P=0.84; I2 = 56%] did not show any significant
association.
Pravastatin
The analysis of pravastatin is shown in Table 2. Data
on pravastatin were available from 25 RCTs
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enrolling 55 470 patients.33,34,40,43,44,46–48,55–
57,59,60,63,68,71,84–92 For cancer, data were available
from 14 RCTs and were made up of 50 770 patients
[1436 (5.67%) statin vs. 1402 (5.52%) control; OR:
1.03, 95% CI 0.95–1.11, P=0.4475; I2 = 0%]. For
rhabdomyolysis, data were available from 10 RCTs
made up of 40 394 individuals [120 (0.60%) sta-
tin vs. 114 (0.56%) controls; OR: 1.08, 95% CI
0.82–1.41, P=0.5914; I2 = 0%]. For diabetes, data
were available from nine RCTs made up of 46 190
patients [882 (3.83%) statin vs. 846 (3.66%) control;
OR: 1.04, 95% CI 0.91–1.19, P=0.5739; I2 = 35%].
For increased AST, data were available from
seven RCTs made up of 35 350 patients [244
(1.38%) statin vs. 237 (1.34%) control; OR: 1.03,
95% CI 0.86–1.23, P=0.7756; I2 = 0%]. For
increased ALT, data were available from four RCTs
made up of 15 200 patients [134 (1.77%) statin vs.
126 (1.65%) control; OR: 1.09, 95% CI 0.85–1.39,
P=0.506; I2 = 0%]. For a 10-fold increase in CK,
data were available from seven RCTs made up of
26 407 patients [156 (1.19%) statin vs. 131
(0.99%) control; OR: 1.21, 95% CI 0.96–1.54,
P=0.1068; I2 = 0%]. No significant association
between pravastatin and the listed adverse events
was shown.
Fluvastatin
The analysis of fluvastatin is shown in Table 3. Data
on fluvastatin were available from nine RCTs enroll-
ing 7387 patients.35–37,50,67,79,93–95 For cancer, data
were available from four RCTs and were made up of
5042 patients [358 (14.24%) statin vs. 392 (15.53%)
control; OR: 0.89, 95% CI 0.75–1.05, P=0.1696;
I2 = 0%]. For rhabdomyolysis, data were available
from four RCTs made up of 5181 individuals [8
(0.31%) statin vs. 3 (0.12%) controls; OR: 2.68,
95% CI 0.68–10.55, P=0.1589; I2 =N/A]. No
meta-analysis could be performed on the incidence
of diabetes for fluvastatin as there was no study that
contained data on this. For increased AST, data were
available from three RCTs made up of 2940 patients
[15 (1.02%) statin vs. 6 (0.41%) control; OR: 2.46,
95% CI 0.93–6.52, P=0.071; I2 = 0%]. For
increased ALT, data were available from three
RCTs made up of 3365 patients [20 (1.20%) statin
vs. 15 (0.89%) control; OR: 1.38, 95% CI 0.62–
3.07, P=0.4356; I2 = 13.7%]. For a 10-fold increase
Table 1 Analysis of atorvastatin adverse events
Adverse effect Random effects (DerSimonian–Laird) I2 (95% CI)
Pooled odds ratio (95% CI) P-value
Cancer 0.902041 (0.735756–1.105906) 0.3214 0 (0–61)
Rhabdomyolysis 1.378303 (0.606514–3.132197) 0.4436 0 (0–61)
Diabetes mellitus a a a
AST increase 2.266165 (1.194625–4.298842) 0.0123 40.5 (0–75.1)
ALT increase 1.735772 (0.496716–6.065652) 0.3877 NA
CK increase 10 1.213217 (0.185757–7.923767) 0.84 55.90 (0–83.40)
aDenotes that not enough information was available to calculate an odds ratio.
Table 2 Analysis of pravastatin adverse events
Adverse effect Random effects (DerSimonian–Laird) I2 (95% CI)
Pooled ORs (95% CI) P-value
Cancer 1.030049 (0.954297–1.111813) 0.4475 0.0 (0.0–47.4)
Rhabdomyolysis 1.077021 (0.821407–1.412179) 0.5914 0.0 (0.0–56.3)
Diabetes mellitus 1.038997 (0.909307–1.187185) 0.5739 35.2 (0.0–69.0)
AST increase 1.026753 (0.85628–1.231165) 0.7756 0.0 (0.0–58.5)
ALT increase 1.087264 (0.849671–1.391295) 0.506 0.0 (0.0–67.9)
CK increase 10 1.214801 (0.95896–1.5389) 0.1068 0.0 (0.0–61.0)
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in CK, data were available from six RCTs made up of
5975 patients [4 (0.13%) statin vs. 8 (0.27%) con-
trol; OR: 0.60, 95% CI 0.18–2.03, P=0.4107;
I2 = 0%]. No significant association between fluvas-
tatin and the listed adverse events was shown.
Lovastatin
The analysis of lovastatin is shown in Table 4. This
meta-analysis included seven RCTs on Lovastatin
that were made up of 16 753 individ-
uals.32,42,69,78,96–98 For the incidence of cancer
after randomization, data were obtained from two
RCTs, comprising 6875 people. No significant asso-
ciation was found between lovastatin and control
groups [258 (7.53%) statin vs. 264 (7.71%) control;
OR: 0.97, 95% CI 0.82–1.17, P=0.778; I2 =N/A].
The impact of lovastatin on the incidence of rhabdo-
myolysis was presented in three RCTs made up of
15 120 patients. No significant association was
found [7 (0.07%) statin vs. 2 (0.04%) control; OR:
1.33, 95% CI 0.27–6.58, P=0.7304; I2 = 0%]. No
meta-analysis could be performed on the incidence
of diabetes for lovastatin as there was only one study
that contained data on this. Three RCTs made up of
15 120 people provided data on the impact of
lovastatin on increased AST levels, for which we
found no statistically significant association [131
(1.31%) statin vs. 51 (1.00%) control; OR: 1.22,
95% CI 0.86–1.74, P=0.2714; I2 = 0%]. Data on
elevated ALT levels were available from two RCTs
made up of 7524 people. The impact of lovastatin
on raised ALT levels was found to be significant
[116 (3.08%) statin vs. 76 (2.02%) control; OR:
1.54, 95% CI 1.15–2.07, P=0.0039; I2 =N/A]. For
a 10-fold increase in CK, data were available from
two RCTs made up of 14 850 patients. There was no
significant association found between lovastatin and
a 10-fold increase in CK levels [38 (0.38%) statin vs.
28 (0.56%) control; OR: 0.85, 95% CI 0.52–1.40,
P=0.5354; I2 =N/A].
Rosuvastatin
The analysis of rosuvastatin is shown in Table 5.
Data obtained for the analysis of rosuvastatin were
made up of six RCTs, comprising 31 230 pa-
tients.39,52,54,64,75,76 There were three RCTs made
up of 25 586 individuals that recorded the incidence
of cancer, for which we found no statistically signifi-
cant association [561 (4.38%) statin vs. 576 (4.61%)
control; OR: 0.97, 95% CI 0.86–1.09, P=0.6173;
Table 3 Analysis of fluvastatin adverse events
Adverse effect Random effects (DerSimonian–Laird) I2 (95% CI)
Pooled ORs (95% CI) P-value
Cancer 0.890431 (0.754528–1.050813) 0.1696 0.0 (0.0–67.9)
Rhabdomyolysis 2.679039 (0.680016–10.554537) 0.1589 NA
Diabetes mellitus a a a
AST increase 2.456471 (0.925877–6.517337) 0.071 0.0 (0.0–72.9)
ALT increase 1.375899 (0.616915–3.068653) 0.4356 13.7 (0.0–76.4)
CK increase 10 0.600161 (0.177812–2.025697) 0.4107 0.0 (0.0–64.1)
aDenotes that not enough information was available to calculate an odds ratio.
Table 4 Analysis of lovastatin adverse events
Adverse effect Random effects (DerSimonian–Laird) I2 (95% CI)
Pooled ORs (95% CI) P-value
Cancer 0.974623 (0.815228–1.165183) 0.7779 NA
Rhabdomyolysis 1.32521 (0.26709–6.575247) 0.7304 0.0 (0.0–72.9)
Diabetes mellitus a a a
AST increase 1.220048 (0.85596–1.739004) 0.2714 0.0 (0.0–72.9)
ALT increase 1.541269 (1.149376–2.066782) 0.0039 NA
CK increase 10 0.853776 (0.517902–1.407474) 0.5354 NA
aDenotes that not enough information was available to calculate an odds ratio.
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I2 = 0%]. Rhabdomyolysis information was available
from five RCTs made up of 26 656 people and no
significant association was found [7 (0.05%) sta-
tin vs. 13 (0.10%) control; OR: 0.73, 95% CI
0.17–3.09, P=0.6696; I2 = 42%]. Data on the inci-
dence of diabetes for rosuvastatin were available
from four RCTs, comprising 30 160 people. There
was a significant association between the use of
rosuvastatin and incidence of diabetes [605
(4.01%) statin vs. 533 (3.54%) control; OR: 1.14,
95% CI 1.01–1.29, P=0.0318; I2 = 1.5%]. No
meta-analysis could be performed on elevated AST
levels for rosuvastatin as there was no study that
contained data on this. Information on elevated
ALT levels was available from five RCTs made up
of 26 656 people. The effect of rosuvastatin on ALT
levels was not found to be significant [59 (0.44%)
statin vs. 48 (0.37%) control; OR: 1.17, 95% CI
0.79–1.72, P=0.4345; I2 = 0%]. Finally, there was
no significant association found between rosuvasta-
tin and a 10-fold increase in CK levels. Information
was available from four RCTs, comprising 8854 in-
dividuals [5 (0.11%) statin vs. 8 (0.19%) control;
OR: 0.52, 95% CI 0.16–1.64, P=0.2642; I2 = 0%].
Simvastatin
The analysis of simvastatin is shown in Table 6. This
meta-analysis included eight RCTs on simvastatin
that were made up of 26 375 individ-
uals.1,38,41,62,99–102 Data on the incidence of
cancer were available from four RCTs made up of
25 433 people. No significant association was found
between simvastatin and the incidence of cancer
[904 (7.11%) statin vs. 903 (7.10%) control; OR:
1.00, 95% CI 0.91–1.10, P=0.953; I2 = 0%].
Rhabdomyolysis information was available from
three RCTs made up of 25 361 patients and found
no significant association [6 (0.05%) statin vs. 3
(0.02%) control; OR: 1.84, 95% CI 0.50–6.79,
P=0.3611; I2 =N/A]. For diabetes, data were avail-
able from two RCTs made up of 24 980 individuals.
No significant association was found between sim-
vastatin and the incidence of diabetes [533 (4.27%)
statin vs. 486 (3.89%) control; OR: 1.10, 95% CI
0.97–1.25, P=0.1299; I2 =N/A]. No meta-analysis
could be performed on elevated AST levels for sim-
vastatin as there was not enough information avail-
able. Data for elevated ALT levels were available
from two RCTs, comprising 24 980 people. There
Table 5 Analysis of rosuvastatin adverse events
Adverse effect Random effects (DerSimonian–Laird) I2 (95% CI)
Pooled ORs (95% CI) P-value
Cancer 0.970027 (0.860884–1.093007) 0.6173 0.0 (0.0–72.9)
Rhabdomyolysis 0.730423 (0.172542–3.092107) 0.6696 42.3 (0.0–82.9)
Diabetes mellitus 1.142353 (1.011682–1.289902) 0.0318 1.5 (0.0–68.4)
AST increase a a a
ALT increase 1.166338 (0.792951–1.715548) 0.4345 0.0 (0.0–64.1)
CK increase 10 0.519735 (0.164764–1.639456) 0.2642 0.0 (0.0–72.90)
aDenotes that not enough information was available to calculate an odds ratio.
Table 6 Analysis of simvastatin adverse events
Adverse effect Random effects (DerSimonian–Laird) I2 (95% CI)
Pooled ORs (95% CI) P-value
Cancer 1.002891 (0.911183–1.103828) 0.953 0.0(0.0–67.9)
Rhabdomyolysis 1.838624 (0.497649–6.79302) 0.3611 NA
Diabetes mellitus 1.102552 (0.971698–1.251027) 0.1299 NA
AST increase a a a
ALT increase 1.421204 (1.032603–1.956047) 0.031 NA
CK increase 10 2.283946 (0.916175–5.69368) 0.0764 NA
aDenotes that not enough information was available to calculate an odds ratio.
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was a significant association between simvastatin
and increased ALT levels [92 (0.74%) statin vs. 65
(0.52%) control; OR: 1.42, 95% CI 1.03–1.96,
P=0.031; I2 =N/A]. Finally, there was no significant
link between the use of simvastatin and a 10-fold
increase in CK levels. Data were available from
two RCTs, comprising 24 980 patients [17 (0.14%)
statin vs. 7 (0.06%) control; OR: 2.28; 95% CI
0.92–5.69, P=0.0764; I2 =N/A].
Indirect comparisons
After the analyses were performed on each of the
different statins, they were compared to each other
to determine if particular adverse events were sig-
nificantly more likely to occur in one type of statin
versus another type. It was found that atorvastatin
is significantly more likely to lead to elevated
AST levels versus pravastatin (OR: 2.21, 95% CI
1.13–4.29), and simvastatin is significantly more
likely to cause a 10-fold increase in CK levels
versus rosuvastatin (OR: 4.39, 95% CI 1.01–19.07)
(Appendix Table S3). No other indirect comparisons
were found to be associated with greater risk of de-
veloping adverse events.
Discussion
Overall, our meta-analysis showed that the use of
statin therapy importantly decreased the risk of
all-cause mortality. Statins were typically safe, al-
though we did observe that the use of rosuvastatin
was significantly associated with an increased rate
of diabetes, the use of atorvastatin was significantly
associated with elevated AST, and the use of lovas-
tatin and simvastatin were significantly associated
with elevated ALT. We also found possible differ-
ences between individual statins for the surrogate
endpoints of AST and CK level changes.
The increased likelihood of developing diabetes
with the use of statin therapy has recently received
attention in the literature. Another meta-analysis
conducted by Sattar et al. also found that statin treat-
ments increase the risk of developing diabetes,
although they concluded that the risk was low
both in absolute terms and when compared with
the reduction in coronary events.103 Similar to
our results, earlier meta-analyses have also shown
significant increases in liver function tests with
statins versus controls.104,105 However, it is import-
ant to note that the recent results of a post hoc ana-
lysis of the GREACE study suggest that statins
may exert beneficial effects also in patients with ele-
vated transaminases.106 Furthermore, our results
indicated that simvastatin was only marginally sig-
nificantly more likely to cause an increase in CK
levels when compared to rosuvastatin. While
others have failed to show significant CK elevations
with statins,104 a meta-analysis of head-to-head
RCTs comparing high- and low-potency statins has
shown a significant increase in CK with higher
doses.105
There are several limitations to consider when
interpreting the results of our analyses. Although
there were large numbers of patients included in
many of the source trials, power to differen-
tiate across interventions may be considered a limi-
tation. We were also limited by the quality of
the source trial publications. Although we con-
ducted a comprehensive search for trials to include
in our meta-analysis, it is possible we may have
missed relevant trials that are not published. In a
similar way, trials may not report specific adverse
events and so these outcomes cannot be evaluated
in a meta-analysis. Additionally, it is possible that
the data extracted from the included trials were ori-
ginally reported incorrectly in the source publica-
tions. Furthermore, data were combined from
multiple trials, each of which differed in patient
populations and study design. However, this is a
commonality in all meta-analyses, and we con-
cluded that it was appropriate to pool these trials a
priori.107
Our meta-analysis focused on specific adverse
events overall as derived from the source trials.
We cannot make any inferences on the impact of
derivatives or other medications on statin metabol-
ism and development of adverse events. In addition,
our study does not make strong inferences on the
dose effect of the individual statins on adverse
events. In our study, AST and diabetes were signifi-
cantly increased with higher doses, but only AST
elevations remained significant compared with
standard dosing. Adverse events associated with
statin treatment may be more likely with higher
doses of specific statins and with combination
therapy.16,105,108
Adverse events less commonly reported in the
source trial publications were not included in our
meta-analysis. Our analysis focused only on mortal-
ity, cancers, rhabdomylosis, diabetes and abnormal-
ities in AST, ALT and CK because these data were
most consistently reported in the source trial publi-
cations. It is important to recognize that other,
less-common adverse events may occur with the
use of statin treatments. For example, transient pro-
teinuria, glucose elevations, renal failure, sleep re-
ductions and sexual dysfunction, among others,
have also been reported as adverse events in RCTs
evaluating the effect of statin treatments.109
In conclusion, since many government health de-
partments have recently recommended that people
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at intermediate risk of CVD begin taking statins, this
could lead to further public health policy changes.
Our study indicates that the use of statin therapy for
CVD is associated with a relatively low risk of ad-
verse events.
Supplementary Data
Supplementary Data are available at QJMED online.
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